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Trends in Hospitalized Acute Myocardial Infarction Patients with 
Heart Failure in Korea at 1998 and 2008
Heart failure (HF) complicating acute myocardial infarction (AMI) is common and is 
associated with poor clinical outcome. Limited data exist regarding the incidence and in-
hospital mortality of AMI with HF (AMI-HF). We retrospectively analyzed 1,427 consecutive 
patients with AMI in the five major university hospitals in Korea at two time points, 1998 
(n = 608) and 2008 (n = 819). Two hundred twenty eight patients (37.5%) in 1998 and 
324 patients (39.5%) in 2008 of AMI patients complicated with HF (P = 0.429). AMI-HF 
patients in 2008 were older, had more hypertension, previous AMI, and lower systolic 
blood pressure than those in 1998. Regarding treatments, AMI-HF patients in 2008 
received more revascularization procedures, more evidence based medical treatment and 
adjuvant therapy, such as mechanical ventilators, intra-aortic balloon pulsation compared 
to those in 1998. However, overall in-hospital mortality rates (6.4% vs 11.1%, P = 0.071) 
of AMI-HF patients were unchanged and still high even after propensity score matching 
analysis, irrespective of types of AMI and revascularization methods. In conclusion, more 
evidence-based medical and advanced procedural managements were applied for patients 
with AMI-HF in 2008 than in 1998. However the incidence and in-hospital mortality of 
AMI-HF patients were not significantly changed between the two time points. 
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INTRODUCTION
Heart failure (HF) is a health problem worldwide, especially in developed countries, 
with a major cause of morbidity and mortality, leading to hospitalization (1, 2). Coro-
nary artery disease including acute myocardial infarction (AMI) is the most common 
cause of HF, while HF is a common serious complication following AMI (3, 4).
 In recent decades, introduction of new medical and interventional treatments, such 
as primary percutaneous revascularization, antiplatelet agents, renin-angiotensin-al-
dosterone system (RAAS) antagonists, statins, and hemodynamic support system such 
as intra-aortic balloon pulsation (IABP) and extracorporeal support system (ECS) have 
been reported to decrease the rate of HF development and in-hospital mortality of AMI 
patients (5-8). However, some other studies could not find any significant decrease in 
trends, especially the incidence of HF after AMI (9, 10). Most studies about the trends 
in the AMI with HF (AMI-HF) were based on data in western countries. However, there 
are few data whether the improvements of AMI treatment have reduced the incidence 
or short term in-hospital mortality of HF in Asian countries (11). Accordingly, we sought 
to investigate temporal trends of AMI-HF in the clinical characteristics, treatment meth-
ods and in-hospital mortality in 1998 and 2008, respectively.
MATERIALS AND METHODS
Study design and population
We studied consecutive AMI patients who admitted in the five major university hospi-
tals in Korea at two time points, 1998 and 2008. First, we used the discharge codes as 
coded by the International Classification of Disease, Tenth Revision, Clinical Mo dification 
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(ICD-10-CM). AMI was defined as I21. We recognized a total of 
1,785 patients with this AMI code. Eligible AMI patients for this 
study had any episodes of chest pain within two weeks of admis-
sion and a positive troponin test or electrocardiogra phic chang-
es (ST-segment deviation ≥ 0.1 mV or pathologic Q wave). A 
total of 1,513 patients was selected for adopting these diagnos-
tic criteria of AMI. The exclusion criteria were as follows: chest 
pain onset started two weeks prior to admission, underlying 
heart failure, estimated life expectancy of less than 12 months.
Baseline characteristics and definition of heart failure
The records of clinical variables were retrieved from patients’ 
electronic medical record. Clinical variables included in the 
analysis were: age, gender, cigarette smoking, vital sign, family 
history of vascular disease, route of admission (emergent de-
partment, out-patient and in-hospital), co-existing conditions 
such as hypertension, diabetes mellitus, cerebrovascular acci-
dent (CVA), history of AMI one month prior to admission, and 
dyslipidemia. The location of infarction, treatment modality, 
additional mechanical treatment, total admission duration, dis-
charge medication, and in-hospital death were also included.
 Shock was defined as systolic pressure lower than 90 mmHg. 
Conservative care of AMI was defined as no reperfusion treat-
ment such as thrombolysis, percutaneous coronary interven-
tion (PCI), and coronary artery bypass graft (CABG). Diagnostic 
criteria of HF were defined as left ventricular ejection fraction 
(LVEF) by echocardiography less than 40% or dyspnea with 
congestion on radiograph. 
Statistical analysis
Continuous variables were expressed as mean ± standard devi-
ation and are compared with the Student’s t-test. Discrete vari-
ables were expressed as percentages and compared with the 
chi-square test or Fisher’s exact test. A multivariate logistic re-
gression analysis was performed in order to identify indepen-
dent predictors for AMI with HF. Variables which were evaluat-
ed in the multivariate logistic regression analysis included us-
ing those with significant association (P < 0.05) in univariate 
logistic regression analysis. 
 A propensity score matching analysis for the predicted prob-
ability of in-hospital mortality in each group was estimated 
with the use of logistic regression model fit with 18 clinically 
relevant factors. Age, gender, types of AMI (ST elevation MI), 
underlying comorbidities such as diabetes, hypertension, dys-
lipidemia, CVA, previous MI and family history, smoking status, 
systolic blood pressure, heart rate, revascularization methods 
(PCI and CABG) and adjuvant therapy (ventilator, intra-aortic 
balloon pump (IABP), inotropes and intensive care unit (ICU) 
care). We created a propensity score matched by attempting to 
match case patients and control patients (a 1:1 match). A near-
est-neighbor-matching algorithm with a “greedy” heuristic (one 
that always implements the best immediate, or local, solution) 
was used to match patients on the demographic characteristics. 
All other analyses were 2-tailed, with clinical significance de-
fined as values of P < 0.05. All statistical analyses were done 
with Statistical Analysis Software package (SAS version 9.1, SAS 
Institute, Cary, NC, USA).
Ethics statement
The study protocol was approved by the institutional review 
board (IRB) at each participating institution. IRB number of 
Seoul National University Hospital was 1102-072-352 and that 
of Severance Cardiovascular Hospital was 4-2011-0075. In-
formed consent was waived by the IRB. 
RESULTS
Characteristics of the study populations
The flow chart was briefly presented to illustrate the selection 
process of study population (Fig. 1). Of 1,785 patients to have 
AMI coded with I21 (ICD-10-CM), we selected 1,513 subjects 
who satisfied the diagnostic criteria of AMI. We excluded 86 pa-
tients; and a total of 1,427 patients were finally selected in this 
study. There were 608 (42.6%) patients with AMI at 1998 and 
819 (57.4%) at 2008. Baseline demographic and clinical charac-
teristics are shown in Table 1. The patients of 2008 were older 
and had high proportion of male patients, hypertension, dys-
lipidemia, and previous AMI but lower prevalence of ST-eleva-
tion MI (STEMI) and received more revascularization treat-
ments such as PCI and CABG and lower thrombolysis treat-
Fig. 1. Study flow chart. AMI, acute myocardial infarction; HF, heart failure; LVEF, left 
ventricular ejection fraction.
1,785 patients (1998 vs 2008)
Selected with Diagnostic Code of AMI
1,513 AMI patients
Content with Diagnosis of AMI
86 Patients excluded
- No AMI (within 2 weeks)
- Known HF
- Estimated life expectancy of <12 months
1,427 AMI patients Analyzed
1998 (n=608) vs 2008 (n=819)
Diagnostic criteria of HF
- Congestion on chest radiograph
- LVEF<40%
552 AMI with HF (38.7%)
1998 (n=228) vs 2008 (n=324)
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Table 1. Comparison of baseline characteristics of AMI between 1998 and 2008
Characteristics 1998 (n = 608) 2008 (n = 819) P value
Demographics
   Male gender, No. (%)
   Age (yr)
438 (72.0)
60.8 ± 12.4
633 (77.4)
62.8 ± 12.4
0.021
0.002
Visit method, No. (%)
   ER
   OPD
   In-hospital
543 (89.3)
60 (9.9)
5 (0.8)
759 (92.7)
57 (7.0)
3 (0.3)
0.021
Transfer from other hospital, No. (%) 176 (29.0) 288 (36.0) 0.006
Diagnostic criteria of AMI, No. (%)
   Chest pain
   Elevated cardiac enzyme
   ST elevation or Q wave
   STEMI
585 (96.5)
459 (77.9)
524 (86.8)
429 (70.6)
762 (93.6)
740 (90.5)
588 (72.8)
483 (59.0)
0.014
< 0.001
< 0.001
< 0.001
Vital sign
   Systolic blood pressure (mmHg)
   Diastolic blood pressure (mmHg)
   Heart rate (/min)
   Shock, No. (%)
128.7 ± 29.4
78.7 ± 19.0
77.6 ± 20.8
35 (5.9)
125.6 ± 28.5
76.4 ± 18.4
79.2 ± 20.3
52 (6.4)
0.052
0.019
0.148
0.692
Medical history, No. (%)
   Diabetes mellitus
   Hypertension
   Dyslipidemia
   Smoking
   CVA
   Previous MI
161 (26.5)
257 (42.5)
84 (14.2)
332 (55.5)
41 (6.8)
30 (4.9)
245 (30.1)
438 (53.5)
156 (19.1)
467 (57.4)
51 (6.2)
105 (12.8)
0.140
< 0.001
0.016
0.430
0.679
< 0.001
Familial history, No. (%) 98 (16.7) 143 (18.2) 0.464
Location of AMI, No. (%)
   Anteroseptal
   Inferolateral
   RV wall
326 (55.7)
332 (56.8)
23 (3.9)
441 (60.3)
436 (60.0)
59 (8.6)
0.093
0.239
0.001
LVEF (%) 47.0 ± 12.1 46.4 ± 13.7 0.503
Treatment method, No. (%)
   Thrombolysis
   PCI
   CABG
   Conservative care
150 (24.7)
329 (54.1)
35 (5.8)
202 (33.2)
18 (2.2)
633 (77.5)
73 (8.9)
105 (12.9)
< 0.001
< 0.001
0.025
< 0.001
Admission duration (day) 11.8 ± 13.6 8.4 ± 9.6 < 0.001
Development of HF, No. (%) 228 (37.5) 324 (39.6) 0.429
ICU care duration (day) 5.9 ± 8.0 4.3 ± 6.8 < 0.001
In-hospital death, No. (%) 20 (3.3) 40 (4.9) 0.071
AMI, acute myocardial infarction; ER, emergency room; OPD, out-patient department; 
STEMI, ST elevation MI; CVA, cerebrovascular accident; MI, myocardial infarction; RV, 
right ventricle; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary inter-
vention; CABG, coronary artery bypass graft; HF, heart failure; ICU, intensive care unit.
ment and had shorter ICU care duration, compared to those in 
1998.
Characteristics of AMI patients with or without HF
Considering the definition of HF as LVEF less than 40% or dys-
pnea with congestion on chest radiograph, a total of 552 (38.7%) 
patients had AMI with HF. The AMI patients with HF were more 
female gender, older, and had a higher incidence of transfer 
from other hospital, absence of chest pain at the initial presen-
tation, lower systolic blood pressure, diabetes mellitus, smok-
ing, CVA, family history and more anteroseptal MI, less re-
ceived PCI, more received CABG, and longer admission and 
ICU care duration (Table 2). Multivariate logistic regression 
analysis showed that old age, transfer from other hospital, ab-
sence of chest pain, lower systolic blood pressure, increased 
heart rate and anteroseptal MI were independent predictors for 
AMI with HF (Table 3). In 1998, old age, transfer from other 
hospital, increased heart rate and anteroseptal MI were inde-
pendent predictors for AMI-HF. In 2008, old age, transfer from 
other hospital, absence of chest pain, lower systolic blood pres-
sure and anteroseptal MI were independently related to AMI-
HF (Table 4). The AMI patients with HF in 2008 were older, had 
a higher prevalence of hypertension, previous AMI, and had 
more active treatment such as adjuvant therapy (e.g. ventilator, 
IABP, extracorporeal membrane oxygenation (ECMO) and ino-
tropics), medical therapy (e.g. antiplatelets, beta blocker, RAAS 
antagonists, and statin) and lower systolic blood pressure com-
pared to those in 1998. However, there was no significant differ-
Table 2. Comparison of baseline characteristics with or without HF in AMI
Characteristics HF (n = 552) No HF (n = 875) P value
Demographics
   Male gender, No. (%)
   Age (yr)
   In 2008 (vs In 1998), No. (%)
389 (70.5)
64.5 ± 12.9
324 (58.7)
682 (78.0)
60.3 ± 11.9
495 (58.6)
0.002
< 0.001
0.442
Visit method, No. (%)
   ER
   OPD
   In-hospital
500 (90.6)
47 (8.5)
5 (0.9)
802 (91.7)
70 (8.0)
3 (0.3)
0.356
Transfer from other hospital, No. (%) 217 (39.4) 247 (28.9) < 0.001
Diagnostic criteria of AMI, No. (%)
   Chest pain
   Elevated cardiac enzyme
   ST elevation or Q wave
   STEMI
506 (92.3)
457 (83.4)
445 (81.1)
363 (65.8)
841 (96.4)
742 (86.4)
667 (77.3)
549 (63.5)
0.001
0.124
0.096
0.333
Vital sign
   Systolic blood pressure (mmHg)
   Diastolic blood pressure (mmHg)
   Heart rate (/min)
   Shock, No. (%)
123.7 ± 30.9
74.8 ± 18.9
83.5 ± 22.3
49 (8.9)
128.9 ± 27.4
79.0 ± 18.4
75.3 ± 18.6
38 (4.4)
0.001
< 0.001
< 0.001
0.001
Medical history, No. (%)
   Diabetes mellitus
   Hypertension
   Dyslipidemia
   Smoking
   CVA
   Previous MI
178 (32.4)
270 (49.0)
90 (16.5)
288 (52.5)
47 (8.5)
49 (8.9)
228 (26.2)
425 (48.8)
150 (17.4)
511 (59.2)
45 (5.2)
86 (9.8)
0.013
0.957
0.663
0.013
0.015
0.578
Familial history, No. (%) 80 (14.9) 161 (19.3) 0.042
Location of AMI, No. (%)
   Anteroseptal
   Inferolateral
   RV wall
334 (64.7)
306 (59.4)
25 (5.1)
433 (54.1)
462 (58.0)
57 (7.3)
< 0.001
0.606
0.128
LVEF (%) 40.3 ± 12.8 53.8 ± 9.2 < 0.001
Treatment method, No. (%)
   Thrombolysis
   PCI
   CABG
   Conservative care
58 (10.5)
317 (57.5)
71 (12.9)
142 (25.8)
110 (12.6)
645 (73.8)
37 (4.2)
165 (18.9)
0.273
< 0.001
< 0.001
0.002
Admission duration (day) 12.9 ± 15.9 7.7 ± 7.4 < 0.001
ICU care duration (day) 6.3 ± 9.1 3.1 ± 3.2 < 0.001
In-hospital death, No. (%) 45 (9.2) 15 (4.0) 0.004
HF, heart failure; AMI, acute myocardial infarction; ER, emergency room; OPD, out-pa-
tient department; STEMI, ST elevation MI; CVA, cerebrovascular accident; MI, myocar-
dial infarction; RV, right ventricle; LVEF, left ventricular ejection fraction; PCI, percutane-
ous coronary intervention; CABG, coronary artery bypass graft; ICU, intensive care unit.
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Table 3. Independent predictors for AMI with HF in overall population (both 1998 and 
2008)
Parameters OR 95% CI P value
Age (yr) 1.024 1.013-1.035 < 0.001
Male gender 0.846 0.610-1.174 0.317
Transfer from other hospital 1.688 1.303-2.185 < 0.001
Chest pain 0.500 0.276-0.906 0.022
Systolic blood pressure (mmHg) 0.992 0.987-0.996 < 0.001
Heart rate (/min) 1.019 1.013-1.026 < 0.001
Diabetes mellitus 1.249 0.954-1.635 0.105
Smoking 0.941 0.710-1.248 0.674
CVA 1.399 0.844-2.319 0.193
Familial history 0.932 0.676-1.285 0.667
Anteroseptal infarction 1.526 1.188-1.960 0.001
AMI, acute myocardial infarction; HF, heart failure; OR, odds ratio; CI, confidence in-
terval; CVA, cerebrovascular accident.
Table 4. Independent predictors for AMI with HF in 1998 and 2008 respectively
Parameters
1998 2008
OR 95% CI P value OR 95% CI P value
Age (yr) 1.023 1.008-1.038 0.003 1.029 1.016-1.043 < 0.001
Transfer from other hospital 1.668 1.132-2.459 0.010 1.696 1.216-2.364 0.002
Chest pain 0.693 0.259-1.859 0.467 0.439 1.216-2.364 0.002
Systolic blood pressure (mmHg) 0.997 0.991-1.003 0.381 0.988 0.982-0.994 < 0.001
Heart rate 1.023 1.008-1.038 0.003 1.019 1.010-1.028 < 0.001
Anteroseptal infarction 1.564 1.089-2.246 0.015 1.335 0.961-1.856 0.085
AMI, acute myocardial infarction; HF, heart failure; OR, odds ratio; CI, confidence interval. 
ence for the incidence and overall in-hospital mortality of AMI-
HF between the two time points (Table 5). To compare in-hos-
pital mortality properly considering the severity of AMI-HF pa-
tients, propensity score matching analysis was done with 18 
relevant clinical variables. However in-hospital mortality was 
not improved between the two time points irrespective of types 
of AMI and revascularization methods (Supplementary Table 
1-3). 
DISCUSSION
The major finding of this study is that despite major advances 
in the management of AMI, the incidence and in-hospital mor-
tality of AMI-HF remained unchanged and still high. During 
the past few decades, advance of interventional treatment (e.g. 
IABP, DES) and induction of new medical treatments such as 
antiplatelet agents, beta-blocker, RAAS antagonists, and statins 
have markedly improved long term prognosis of patients with 
AMI (5-7, 12). In our study, while short term in-hospital mortal-
ity rate (3.3% vs 4.9%) was comparable to other previous studies 
but it was not decreased from 1998 to 2008. Considering the 
disparity in clinical severity between two time points in our 
study, increased hospital accessibility and advanced salvage 
treatments of high-risk AMI patients in recent time point may 
contribute to these unchanged trends. 
 Regarding HF complicating AMI, Hellermann et al. (13) show-
ed that compared to 1979, there was a 28% reduction in the in-
cidence of heart failure after AMI at 1994 in the Unites States. In 
Framingham Heart Study, compared with the period 1970 to 
1979, the investigators observed higher risk of heart failure and 
lower risk of mortality rate in the period 1990 to 1999 (9). Con-
sistently, in Canada, 5 yr rate of HF development increased by 
25%, whereas 5 yr mortality rate after MI decreased by 28% (10). 
The incidence of AMI with HF did not change from 1998 to 2008 
in our study, comparable to other studies (4). However, most 
epidemiologic studies about the trends in the incidence of HF 
after AMI have been conducted in Western countries. Recently, 
the striking differences in outcomes after AMI were observed in 
the different ethnic group studies. For instance, Chinese had 
higher short-term mortality, compared with South Asian and 
white patients (11). In our study, even after extensive propensi-
ty score matching analysis, in-hospital mortality was not im-
proved between the two time points irrespective of types of 
AMI and revascularization methods. Rather, in hospital mortal-
ity of AMI-HF seems to be higher in 2008 than in 1998 (11.1% vs 
6.4%, P = 0.071), although it does not reach statistical signifi-
cance. Higher referral rate from other hospital (41.7% in 2008 vs 
36.1% in 1998, P = 0.111), higher incidence of shock patients 
(11.1% in 2008 vs 5.7% in 1998, P = 0.069) and higher incidence 
of previous MI (13.0% in 2008 vs 3.1% in 1998, P < 0.001) might 
contribute to this finding. However, nationwide large prospec-
tive study with non-selected AMI patients would clarify the ac-
tual temporal trends of in-hospital mortality. In addition, future 
studies about the trends of HF following AMI in Asian region 
might be followed to confirm the disparities between western 
and East-Asian patients. 
 The studies to decipher the predictors for HF in AMI have 
been conducted. Najafi et al. (4) showed that age, current smok-
er, hypertension, diabetes, Q-wave and anterior wall MI were 
independent predictors of early-onset HF after MI. Ezekowitz 
et al. (10) reported that male gender, hypertension, diabetes, 
atrial fibrillation and CVA were associated with the risk for de-
veloping HF during hospitalization in MI. In HORIZONS-AMI 
trial, multivariate predictors of new-onset HF following PCI in 
STEMI were history of MI, LVEF, female and insulin-treated di-
Youn J-C, et al. • Temporal Trends in AMI with Heart Failure in Korea
548  http://jkms.org http://dx.doi.org/10.3346/jkms.2014.29.4.544
analysis (Table 3). Most of them were related to hemodynamic 
status (lower systolic blood pressure, increased heart rate) and 
co-morbid medical conditions (e.g. hypertension, diabetes, 
and CVA). AMI patients with HF in 2008 were older and, had a 
higher prevalence of hypertension, previous AMI, adjuvant 
therapy and lower systolic blood pressure than those in 1998. 
Considering these lines of findings, older age, transfer from 
other hospital, and lower systolic blood pressure at admission 
were important risk factors for HF development following AMI 
in Korea. Therefore more attentions and early treatments about 
concomitant HF should be paid in AMI patients with low sys-
tolic blood pressure and underlying medical diseases.
 This study has several limitations. First, although we sought 
to analyze all consecutive AMI patients at two time periods, se-
lection of patients was dependent on ICD codes of medical da-
tabase without detailed clinical information such as laboratory 
and angiographic findings. Even though utilizing an adminis-
trative database with established quality control, the absence of 
validation of diagnosis and subsequent coding might be an im-
portant limitation. Though we excluded patients with underly-
ing heart failure, there are possibilities that patient with asymp-
tomatic LV dysfunction with no apparent heart failure symptom 
(NYHA II) could be enrolled as a patient with HF complicated 
AMI in this study. Second, because the data pertain only to one 
city and two times of year, this result may not be applicable to 
other nationwide patients. Third, the lack of long-term follow 
up data after discharge might underestimate overall HF inci-
dence rates and prevent further analysis with long-term mor-
tality of AMI-HF. Lastly but most importantly, we could not an-
alyze the long-term outcome of AMI-HF patients. Therefore 
further prospective studies are required to reveal whether re-
cent development of procedural managements and more evi-
dence-based practice might improve midterm as well as long 
term survival after index admission of AMI-HF patients.
 In conclusion, more evidence-based medical and advanced 
procedural managements were applied with patients with AMI 
in 2008 than in 1998, but there were no significant differences 
in the incidence of HF during hospitalization and in-hospital 
mortality following AMI between 1998 and 2008 in Korea. 
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   ARB
   CCB
   Digoxin
   Aldosterone antagonist
   Other diuretics
   Statin
   Other lipid lowering agent
   ACEI/ARB+Beta-blocker
170 (86.3)
0 (0.0)
65 (33.0)
5 (2.6)
83 (42.1)
101 (51.3)
4 (2.0)
58 (29.4)
23 (11.7)
6 (3.0)
56 (28.4)
33 (16.8)
2 (1.0)
45 (23.0)
242 (86.1)
224 (79.4)
3 (1.1)
30 (10.6)
156 (55.3)
117 (41.8)
52 (18.5)
52 (18.4)
10 (3.5)
63 (22.3)
75 (26.6)
207 (73.4)
6 (2.1)
107 (38.1)
0.957
< 0.001
< 0.001
0.001
0.005
0.041
< 0.001
0.005
0.001
< 0.001
0.658
< 0.001
0.353
< 0.001
Number of anti-platelet, No. (%)
   0
   1
   2
   3
24 (12.3)
103 (52.8)
68 (34.9)
0 (0)
34 (12.1)
26 (9.3)
194 (69.3)
26 (9.3)
< 0.001
Echocardiogram, No. (%) 189 (82.9) 277 (85.5) 0.407
LVEF (%) 41.4 ± 12.3 39.6 ± 13.0 0.129
Admission duration (day) 14.71 ± 18.68 11.69 ± 13.44 0.037
ICU care duration (day) 7.05 ± 9.79 5.82 ± 8.54 0.139
In-hospital death, No. (%) 13 (6.4) 32 (11.1) 0.071
AMI, acute myocardial infarction; HF, heart failure; STEMI, ST elevation MI; LVEF, left 
ventricular ejection fraction; IABP, intra-aortic balloon pump; ECMO, extracorporeal 
membrane oxygenation; Gp, glycoprotein; CVA, cerebrovascular accident; MI, myo-
cardial infarction; ACEI, angiotension converting enzyme inhibitor; ARB, angiotensin II 
receptor blocker; CCB, calcium channel blocker; ICU, intensive care unit. 
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Supplementary Table 1. Propensity score matching analysis for in-hospital mortality 
in AMI patients with HF between 1998 and 2008
Variables 1998 (n = 128) 2008 (n = 128) P value
Gender
   Male
   Female
88 (68.75)
40 (31.25)
90 (70.31)
38 (29.69)
0.763
Age (yr) 62.37 ± 12.54 62.73 ± 12.94 0.791
STEMI, No. (%)
   Yes
   No
88 (68.75)
40 (31.25)
91 (71.09)
37 (28.91)
0.662
Hypertension
   Yes
   No
54 (42.19)
74 (57.81)
58 (45.31)
70 (54.69)
0.617
Diabetes mellitus
   Yes
   No
41 (32.03)
87 (67.97)
42 (32.81)
86 (67.19)
0.898
CVA
   Yes
   No
11 (8.59)
117 (91.41)
11 (8.59)
117 (91.41)
> 0.999
Previous MI
   Yes
   No
3 (2.34)
125 (97.66)
2 (1.56)
126 (98.44)
> 0.999
Dyslipidemia
   Yes
   No
20 (15.63)
108 (84.38)
19 (14.84)
109 (85.16)
> 0.999
Smoking
   Yes
   No
63 (49.22)
65 (50.78)
64 (50.00)
64 (50.00)
0.891
Family history
   Yes
   No
18 (14.06)
110 (85.94)
21 (16.41)
107 (83.59)
0.728
SBP (mmHg) 124.47 ± 27.72 127.43 ± 29.73 0.426
Heart rate (/min) 82.31 ± 20.43 82.70 ± 20.56 0.877
PCI
   Yes
   No
79 (61.72)
49 (38.28)
82 (64.06)
46 (35.94)
0.668
CABG
   Yes
   No
13 (10.16)
115 (89.84)
13 (10.16)
115 (89.84)
> 0.999
Ventilator
   Yes
   No
19 (14.84)
109 (85.16)
18 (14.06)
110 (85.94)
> 0.999
IABP
   Yes
   No
15 (11.72)
113 (88.28)
17 (13.28)
111 (86.72)
0.845
Inotropics
   Yes
   No
33 (25.78)
95 (74.22)
33 (25.78)
95 (74.22)
> 0.999
ICU care duration (day) 6.13 ± 8.14 6.07 ± 10.84 0.960
In-hospital mortality, No. (%) 
   Yes
   No
6 (4.69)
122 (95.31)
11 (8.59)
117 (91.41)
0.332
AMI, acute myocardial infarction; HF, heart failure; STEMI, ST elevation MI; CVA, cere-
brovascular accident; MI, myocardial infarction; SBP, systolic blood pressure; PCI, 
percutaneous coronary intervention; CABG, coronary artery bypass graft; IABP, intra-
aortic balloon pump; ICU, intensive care unit.
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Supplementary Table 2. Propensity score matching analysis for in-hospital mortality 
in AMI patients with HF treated by PCI between 1998 and 2008
Variables 1998 (n = 71) 2008 (n = 71) P value
Gender
   Male
   Female
51 (71.83)
20 (28.17)
51 (71.83)
20 (28.17)
> 0.999
Age (yr) 60.23 ± 12.60 59.79 ± 12.87 0.813
STEMI, No. (%)
   Yes
   No
57 (80.28)
14 (19.72)
56 (78.87)
15 (21.13)
> 0.999
Hypertension
   Yes
   No
29 (40.85)
42 (59.15)
33 (46.48)
38 (53.52)
0.505
Diabetes mellitus
   Yes
   No
21 (29.58)
50 (70.42)
25 (35.21)
46 (64.79)
0.346
CVA
   Yes
   No
5 (7.04)
66 (92.96)
2 (2.82)
69 (97.18)
0.453
Previous MI
   Yes
   No
0 (0.00)
71 (100.00)
0 (0.00)
71 (100.00)
> 0.999
Dyslipidemia
   Yes
   No
13 (18.31)
58 (81.69)
11 (15.49)
60 (84.51)
0.839
Smoking
   Yes
   No
36 (50.70)
35 (49.30)
35 (49.30)
36 (50.70)
0.866
Family history
   Yes
   No
12 (16.90)
59 (83.10)
10 (14.08)
61 (85.92)
0.832
SBP (mmHg) 126.54 ± 25.36 125.30 ± 29.36 0.790
Heart rate (/min) 81.72 ± 18.63 80.44 ± 20.40 0.680
Ventilator
   Yes
   No
2 (2.82)
69 (97.18)
4 (5.63)
67 (94.37)
0.500
IABP
   Yes
   No
9 (12.68)
62 (87.32)
8 (11.27)
63 (88.73)
> 0.999
Inotropics
   Yes
   No
14 (19.72)
57 (80.28)
16 (22.54)
55 (77.46)
0.832
ICU care duration (day) 4.11 ± 2.88 4.77 ± 9.31 0.567
In-hospital mortality, No. (%)
   Yes
   No
1 (1.41)
70 (98.59)
3 (4.23)
68 (95.77)
0.500
AMI, acute myocardial infarction; HF, heart failure; PCI, percutaneous coronary inter-
vention; STEMI, ST elevation MI; CVA, cerebrovascular accident; MI, myocardial in-
farction; SBP, systolic blood pressure; IABP, intra-aortic balloon pump; ICU, intensive 
care unit.
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Supplementary Table 3. Propensity score matching analysis for in-hospital mortality 
in patients with STEMI with HF treated with PCI between 1998 and 2008
Variables 1998 (n = 38) 2008 (n = 38) P value
Gender
   Male
   Female
28 (73.68)
10 (26.32)
28 (73.68)
10 (26.32)
> 0.999
Age (yr) 61.29 ± 11.52 61.29 ± 13.64 > 0.999
Hypertension
   Yes
   No
15 (39.47)
23 (60.53)
16 (42.11)
22 (57.89)
0.808
Diabetes mellitus
   Yes
   No
7 (18.42)
31 (81.58)
10 (26.32)
28 (73.68)
0.607
CVA
   Yes
   No
3 (7.89)
35 (92.11)
3 (7.89)
35 (92.11)
> 0.999
Previous MI
   Yes
   No
0 (0.00)
38 (100.00)
0 (0.00)
38 (100.00)
> 0.999
Dyslipidemia
   Yes
   No
5 (13.16)
33 (86.84)
4 (10.53)
34 (89.47)
> 0.999
Smoking
   Yes
   No
24 (63.16)
14 (36.84)
25 (65.79)
13 (34.21)
> 0.999
Family history
   Yes
   No
6 (15.79)
32 (84.21)
7 (18.42)
31 (18.58)
> 0.999
SBP (mmHg) 126.95 ± 29.39 120.18 ± 27.37 0.286
Heart rate (/min) 80.03 ± 20.26 81.05 ± 25.46 0.842
Ventilator
   Yes
   No
6 (15.79)
32 (84.21)
5 (13.16)
33 (86.84)
> 0.999
IABP
   Yes
   No
8 (21.05)
30 (78.95)
8 (21.05)
30 (78.95)
> 0.999
Inotropics
   Yes
   No
11 (28.95)
27 (71.05)
14 (36.84)
24 (63.16)
0.549
ICU care duration (day) 4.74 ± 3.77 4.32 ± 5.17 0.711
In-hospital mortality, No. (%)
   Yes
   No
2 (5.26)
36 (94.74)
3 (7.89)
35 (92.11)
> 0.999
STEMI, ST elevation MI; HF, heart failure; PCI, percutaneous coronary intervention; 
CVA, cerebrovascular accident; MI, myocardial infarction; SBP, systolic blood pres-
sure; IABP, intra-aortic balloon pump; ICU, intensive care unit.
